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Abstract:  In order to evaluate the effects of hyperthermia on adriamycin cardiomyopathy and its relationship with heat
shock protein induction and myosin accumulation, female Sprague-Dawley rats (21–24 days) were randomized into four
groups: the control, adriamycin, temperature and temperature-adriamycin groups.  Adriamycin was injected i.v.  at a dose
of 27 mg/Kg (0.1 ml).  The rats were exposed to a temperature of 45ºC for 35 min, followed by a recovery (1 h) at
room temperature prior to adriamycin treatment.  Body weight was recorded weekly.  The thickness of the ventricular
wall and percentage of cellular damage were biometrically and ultrastructurally evaluated, respectively.  Heat shock
protein 25 and myosin accumulation were determined through Western blot analysis.  The determinations were carried
out monthly until the third month after treatment.  At eight and twelve weeks after treatment, the thickness of the
ventricular wall seemed to decrease in the adriamycin-treated rats in relation to the other groups.  An electron
microscopic analysis of the adriamycin group’s left ventricular wall samples, showed more sarcomeric changes and loss
of myofibrils than the control, temperature and temperature-adriamycin groups.  At 24 hours after treatment with
adriamycin, higher levels of heat shock protein 25 and myosin were observed (week 0) in the temperature-adriamycin
group than in the control and adriamycin groups (4, 8 and 12 weeks).  Hyperthermia was confirmed by a multivariate
approach to induce heat shock protein 25 and myosin, which would strengthen cardiac-sarcomeric myosin arrangement.
(J Toxicol Pathol 2010; 23: 235–243)
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Introduction
The clinical efficacy of the antitumor antibiotic drug
adriamycin is severely limited by its cardiotoxic effects1,2.
In an experimental rat model of cardiomyopathy, this potent
cardiotoxin causes a significant reduction in body weight,
left ventricular wall thickness and heat shock protein 70 and
25 (Hsp70, Hsp25) accumulations3.  Moreover, the ventricu-
lar action potential duration is significantly shortened in the
presence of adriamycin, while the incidence of ventricular
fibrillation is significantly enhanced4.  All this, as well as
serious degenerations at the subcellular level, have previ-
ously been demonstrated3.
In this regard, selective inhibition of cardiac muscle
gene expression is among the earliest events in adriamycin
cardiotoxicity, which may lead to mostly irreversible and
sometimes fatal cardiomyopathy in patients treated with
adriamycin5, 6.  Furthermore, rats injected with adriamycin
showed a dose-dependent decrease in the levels of mRNAs
for alpha-actin, troponin I, myosin light chain 2 and M iso-
form of creatine kinase in cardiac muscles.  These selective
changes in gene expression in cardiocyte cultures and car-
diac muscles precede classical ultrastructural changes and
may explain the myofibrillar loss that characterizes adriamy-
cin cardiac injury7.  In this sense, different cardioprotective
strategies have been evaluated, including L-carnitine, which
reduces the severity of late adriamycin cardiomyopathy, by
promoting the induction of Hsp253. 
Heat stress is associated with the induction of heat
shock proteins (Hsps), which in turn modulates cellular sur-
vival or death8.  In vitro results show that heat shock
induced-Hsp27 can protect against adriamycin induced tox-
icity in cardiac H9c2 cells 9.  The depletion of Hsp27 in car-
diac H9c2 cells by small interfering siRNA also reduced the
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viability against adriamycin, confirming that Hsp27 does
protect cardiac cells against adriamycin-induced toxicity10.
Transgenic mice with cardiac-specific overexpression of
Hsp27 attenuate adriamycin-induced cardiac dysfunction in
mice11.  The overexpression of Hsp20 inhibits adriamycin
triggered cardiac injury possibly dependent on Akt kinase
activation and the attenuation of oxidative stress 12.  How-
ever, important issues still remain unresolved including, the
biological role of Hsp25 in structural cardiac organization in
vivo during short and long term adriamycin intoxication and
its relationship with myosin accumulation as a potential
molecular event associated with cardiac protection induced
by thermal stress.  In this work, our aim was to evaluate the
effect of hyperthermia in vivo by using an animal experimen-
tal model of adriamycin-induced very late cardiotoxicity set
up with differences in mortality, body weight, ventricular
wall thickness, cellular damage, Hsp25 and myosin accumu-
lation among control and treated animals at 0, 4, 8 and 12
weeks after treatment. 
Materials and Methods
Animals
Female Sprague-Dawley rats (n=80) at approximately
21–24 days of age and weighing 40–60 g were obtained from
the Instituto Venezolano de Investigaciones Científicas
(Caracas, Venezuela).  The rats were allowed free access to
standard diet and water ad libitum at room temperature,
which was 23ºC.  The animals were kept according to the
norms specified in the “Guide for the Care and Use of Labo-
ratory Animals” of the U.S.  National Institutes of Health
(NIH publication No.  85–23, revised 1996) and related eth-
ical regulations of the Universidad Central de Venezuela,
Instituto de Medicina Tropical.
Materials
The adriamycin was purchased from Badan (Caracas,
Venezuela).  All biochemical compounds and monoclonal
antibodies were obtained from Sigma-Aldrich (St. Louis,
MO, USA).  The compounds for structural and ultrastruc-
tural studies were purchased from Electron Microscopy Sci-
ences (Hatfield, PA, USA).
Adriamycin treatment
The animals were randomized into the following four
groups (n=20 each): the control (Control), adriamycin (Adr),
temperature (Temp) and temperature-adriamycin (Temp-
Adr) groups.  The drug was injected i.v. in the caudal vein to
a cumulative dose of 27 mg/kg body weight, divided into
three sub-doses of 9 mg/kg body weight/ 0.1ml/day applied
at 3-day intervals.  Each of the Control group rats was
injected i.v. with 0.1 ml of sterile water, following the pat-
tern protocol described in Fig. 1.
Thermal stress
Much of the existing data regarding Hsp responses to
stress fails to exclude the potential acute effects of anesthetic
agents used in experimental protocols13 and the effects of
immunomodulators on anti-Hsp antibodies14.  Temp-Adr
group rats were exposed to a temperature of 45ºC for 35 min
prior to adriamycin treatment, without anesthesia, in a pad-
ded wooden cage with thermal and humidity controls, after
which they were allowed to recover at 23ºC for 1h; a similar
method has already been reported15 .  Finally, 24 hours after
the third adriamycin sub-dose at weeks 0 and 4, 8, and 12
after treatment, the rats’ hearts were removed for biometric,
ultrastructural and biochemical studies (Fig. 1).
Biometric study
Paraffin-embedded hearts were sectioned at 4-μm inter-
vals and stained with H&E.  The sectioned free left ventricu-
lar walls were examined by light microscopy and drawn with
an adapted camera lucida.  The thicknesses of the free left
ventricular walls were determined by means of SigmaScan
image analysis software.
Ultrastructural study
Left ventricular free wall samples were first fixed with
Karnovsky’s fixative (320 mosmol pH 7.4 for 2 h at 4ºC),
then post-fixed in osmic acid (0.12 M 2% osmium tetroxide,
320 mosmol, pH 7.4, for 2 h at 4ºC), dissolved in a phosphate
buffer (1 h at room temperature) and then dehydrated in ace-
tone (50%, 70%, 80%, 95% and 100%; 30 min each).
Fig. 1. Heat stress and drug administration protocol.  The animals
were randomized into the followings four groups (n=20 each
group): the control (Control), Adriamycin (Adr), Temperature
(Temp) and Temperature-Adriamycin (Temp-Adr) groups.
The rats of the control group were injected with sterile water
(0.1 ml i.v; H2O; arrow).  Adriamycin was injected i.v.  in
three sub-doses of 9 mg/kg body weight/0.1 ml/day (Adr;
dashed arrow) applied at 3-day intervals to a cumulative dose
of 27 mg/kg body weight.  The Temp-Adr group rats were
exposed to a temperature of 45ºC for 35 min (HS; arrowhead)
prior to adriamycin treatment and allowed to recover at 23ºC
for 1 h.  At 24 hours after the third adriamycin sub-dose 0, 4,
8 and 12 weeks after treatment, the hearts of the rats were
removed (R; downwards arrow) for biometric, ultrastructural
and biochemical studies.Strauss, Rada, Tejero et al. 237
Finally, they were embedded in polymerizing epoxy resin.
After embedding, thin sections were cut, stained with satu-
rated uranyl acetate (5 min) and lead citrate (3 min) and
examined with a transmission electron microscope (Hitachi
300, 75 kV).
Cellular damage
The percentage of cellular damage was interpreted fol-
lowing a semi-quantitative scoring cytogram system.  Values
ranging from 0–4 were assigned to four cellular damage
zones observed in each grid (3 grids) for all experimental
groups.  In addition, 6 ultrastructural variables were taken
into consideration (nucleus, contractile apparatus, mitochon-
dria, endoplasmic reticulum, membranes, extracellular find-
ings).  After observation (× 6300), the 100% level of damage
was related to a maximal theoretical value of 72 (4 damage
zones × 3 grids × 6 ultrastructural variables)16.
 Western blot analysis
Free left wall ventricular tissue was homogenized (4ºC;
1 ml extraction buffer, Tris-HCl 20 mM, EDTA 2 mM,
PMSF 1 mM, pH 7.4) using a Potter-Elvehjem tissue
grinder.  The samples were centrifuged (14000 RPM/10
min), and the pellet was discarded.  The Hsp25 and myosin
content in the supernatant of the homogenized heart tissue
was determined by Western blot analysis.  Protein samples
were diluted with a 4 × Laemmli buffer solution.  Equal
amounts of protein samples (20 μg per lane) were applied to
10% polyacrylamide gels and separated by SDS-PAGE in
duplicated gels using a Bio-Rad Mini-Gel system.  One gel
was stained with Coomassie Brilliant Blue G-250 to confirm
the equivalence of loading concentrations and the adequacy
of the sample preparation, while the second gel was trans-
ferred to a nitrocellulose membrane and stained with Pon-
ceau Red before recognizing Hsp25 and myosin.  Then, the
membranes were washed in PBS (pH 7.4), 0.1% Tween 20
and 5% fat free milk to block non-specific binding sites and
incubated with mouse monoclonal IgG against Hsp25
(Sigma, St. Louis, MO, USA; clone IAP-28) or myosin
smooth muscle (Sigma, St. Louis, MO, USA; clone hSM-V)
in a 1:500 dilution.  After washing, a secondary antibody
was used.  The protein bands were detected using an
enhanced chemiluminescent substrate and exposed to films.
The relative levels of the protein bands were determined
with the use of optical densitometry (GS-800 densitometer
and the Quantity One Program; Bio-Rad).
Statistical analysis
A 2-way analysis of variance (ANOVA) was under-
taken to evaluate the similarities among the media of all the
variables included in this study17.  The Duncan’s post hoc
test (or multiple comparison test) can be used to determine
the significant differences between group means in an
ANOVA setting and is based on range statistics18.  Statisti-
cally significant differences from the control and Adr groups
are indicated with a dagger and double dagger respectively
in Figs 2, 3, 4, 7 and 8.
The values showed in the Cartesian and bar graphs are
expressed as standard errors of the mean.  In addition, the
statistical analysis of the data generated was also evaluated
with a Principal Component Analysis (PCA) because of the
multivariate condition of the experimental design.  PCA
describes the data behavior of the 4 groups, Control, Adr,
Temp and Temp-Adr, at the times studied (0, 4, 8 and 12
weeks) as a function of the analyzed variables (mortality,
body weight, left ventricular wall thickness, cell damage,
Hsp25 OD/mm2 and myosin OD/mm2) in a single rectangu-
lar Cartesian plane (biplot).  The PCA was computed with
the Multivariate Statistical Package (MVSP).  The data gen-
erated was interpreted biologically19.  The expected proba-
bility was fitted to p<0.05.
Results
Mortality
In the Adr group, the cumulative mortality reached
75%, in contrast to the Control, Temp and Temp-Adr groups,
where 0, 0 and 30% mortality was detected, respectively
(Fig. 2). 
Body weight
The drug applied to the Adr group caused a significant
reduction in body weight from week 4 compared with the
Control group, which showed continuous weight gain
throughout the experiment.  The animals exposed to hyper-
thermia before treatment had a lower weight gain at weeks 4
and 12 compared with the Control rats.  The Temp-Adr
group experienced a decrease in body weight after week 4
until week 12 (Fig. 3). 
Fig. 2. Cumulative mortality during the experimental period for all
groups.  An increase in mortality was observed in the Adr
group (75%) in contrast to the results of the Control, Temp
and Temp-Adr rats, which showed 0, 0 and 30% mortality,
respectively.  The column corresponds to the mean
cumulative mortality, and the whisker corresponds to the
standard error.  ANOVA and the Duncan post hoc test
showed significance differences among groups (p<0.05). 238 Hyperthermic Protection in Adriamycin Cardiomyopathy
Biometric study
The Adr and Temp-Adr groups experienced a reduction
in the thickness of the left ventricular wall from week 8 to
week 12 compared with the Control and Temp groups,
respectively.  The reduction for the Adr group seems to be
bigger than that for the Temp-Adr group, both at 8 and 12
weeks.  Nevertheless, no significant differences in left ven-
tricular wall thickness were observed in the Control and Adr
groups between 0 and 4 weeks after the beginning of the
adriamycin treatment (Fig. 4).
Ultrastructural study
In week 0 (Fig. 5 A–D), the left ventricular cardiac wall
tissue samples from the Control (A), Adr (B), Temp (C) and
Temp-Adr (D) groups all showed normal appearances.  Four
weeks after treatment (Fig. 5, E–H), a few changes were
observed in the samples from the Adr (F) and Temp-Adr (H)
groups including sarcomeric and mitochondrial modifica-
tions and the presence of vacuoles and lipid droplets, in con-
trast to the samples from Control (E) and Temp (G) groups.
In addition, at 8 (Fig. 6 A–D) and 12 weeks (Fig. 6 E–H)
after treatment, the Adr (B, F) and Temp-Adr (D, H) tissue
samples showed a diffuse disarray of myofibrils and an
abnormal pattern of the bands in the sarcomere, disorganiza-
tion in the contractile element, degeneration of fibers and
loss of the characteristic sarcomeric structure, giving the
appearance of a lax tissue, as well as the presence of a signif-
icant perinuclear edema and a perinuclear cistern exhibiting
invaginations over its whole arrangement.
Cellular damage
The resulting damage for each condition was expressed
as a percentage of the maximal theoretical damage (Fig. 7).
The Adr group showed the highest percentage of cellular
damage in contrast to the samples from the Temp-Adr group,
which had less cellular damage (8 and 12 weeks).  However,
the smallest amounts of damage were clearly observed in the
Control and Temp groups. 
Western blot analysis
Compared with the Control group, the Adr group
showed a notable increase in Hsp25 accumulation.  Two
bands in particular were recognized by the anti-Hsp25 anti-
body, corresponding to weeks 0 and 8 after adriamycin treat-
ment.  In contrast, the Temp-Adr group revealed the densest
band recognized by the same antibody corresponding to
week 0.  Hsp25 was also recognized in the Temp group,
especially at 0 and 8 weeks (Fig. 8A).  Consistent with the
highest accumulation of Hsp25, myosin also had its densest
band in the Temp-Adr treated group at 0 week.  This result
was similar to that of the Temp group (0 week).  However,
the highest value of myosin was seen in the control group at
week 4 as a result of the normal growth of the rats in this
group.  Myosin accumulation decreased more in both Adr
treated groups from week 8.  (Fig. 8B). 
Fig. 3. Weight gain during the experimental period. Adriamycin
caused a significant reduction in body weight from week 4
compared with the Control and Temp groups.  The Temp-Adr
group experienced a decrease in body weight from week 4
until week 12.  The Control, Adr, Temp and Temp-Adr rats
are indicated by empty squares, empty diamonds, empty
triangles and full circles, respectively.  Values are shown as
the means ± standard errors.  ANOVA and Duncan post hoc
test showed significance differences among groups (p<0.05).
Statistically significant differences compared with the control
and Adr groups are indicated with a dagger and double-
dagger, respectively.  
Fig. 4. Left ventricular wall thickness.  The wall thickness reduction
in the Adr group seems to be bigger than that in the Temp-
Adr group at 8 and 12 weeks.  The Control, Adr, Temp and
Temp-Adr groups are indicated by white columns, black
columns, dotted columns and slashed columns, respectively.
Values are shown as the means ± standard errors.  ANOVA
and Duncan post hoc test showed significance differences
among groups (p<0.05).  Statistically significant differences
compared with the control and Adr groups are indicated with
a dagger and double-dagger, respectively.Strauss, Rada, Tejero et al. 239
Statistical analysis
The ANOVA and Duncan post hoc test showed the dif-
ferences among variables with p<0.05 in each of the ana-
lyzed variables.  The PCA biplot represented the influence of
each variable in a vectorial manner referred to as autovectors
(Fig. 9).  The autovectors indicated the direction and mean-
ing of change in each variable.  Autovectors pointing in the
same direction correlated directly in the PCA model together
with a similar change in the variables.  Mortality and cell
damage were clear examples.  On the other hand, autovec-
tors pointing in opposite directions were inversely corre-
lated.  Mortality and cell damage were found to be antipodal
variables for myosin expression.  Body weight and left ven-
tricle wall thickness were diametric variables, since the body
weight loss was associated conversely with a reduction in the
thickness of the left ventricle wall.  The PCA model also
quantitatively demonstrated that at the beginning of the
experiments (0 weeks) there was a high Hsp25 accumulation
and not much increase in body weight.  From 4 to 12 weeks,
the Hsp25 accumulation diminished and body weight
Fig. 5. Electron photomicrographs of free left wall ventricular
cardiac tissue at 0 and 4 weeks after treatment.  Cardiac tissue
showed normal appearances in all four groups at 0 week (A–
D).  A small number of sarcomeric and mitochondria
alterations and the presence of vacuoles and lipid droplets
were observed in the Adr and Temp-Adr samples compared
with the Control and Temp samples at 4 weeks (E–H) after
treatment.  Images A and E, B and F, C and G and D and H
are of Control, Adr, Temp and Temp-Adr tissues,
respectively (magnification, ×6280; scale bar=2.3 μm; taken
with 75 kV).
Fig. 6. Electron photomicrographs of left ventricular wall cardiac
tissue at 8 and 12 weeks after treatment.  Myofibrillar
disarrangement, abundant intermyofibrillar spaces and
disassembly, rupture and loss of myofibrils were observed in
the Adr and Temp-Adr samples in contrast to the Control and
Temp samples, which had normal patterns of cardiac tissue.
The Adr group alterations seemed to be larger than those of
the Temp-Adr group both at 8 and 12 weeks after treatment.
Images A and E, B and F, C and G and D and H are of
Control, Adr, Temp and Temp-Adr tissues, respectively
(magnification, ×6280; scale bar=2.3 μm; taken with 75 kV). 240 Hyperthermic Protection in Adriamycin Cardiomyopathy
increased. 
Discussion
In this study, we demonstrated that heat stress precondi-
tioning of adriamycin-treated rats led to a remarkable
increase in Hsp25 accumulation.  This first cellular response
was directly linked to an increase of myosin in addition to
fewer cardiac subcellular toxic injuries.  Stress response
involves the rapid and transient increase in a specific set of
Hsps20, and in this sense, protein transcription and transla-
tion are halted, presumably to alleviate the burden of mis-
folded proteins in the cell21.  Although Hsp25 was induced
by hyperthermia, we did not compare the Hsp25 accumula-
tion to others Hsps.  However, our observations could not
exclude the role of others Hsps because, for example, over-
expression of Hsp27 in the human heart upregulated both
Hsp32 and Hsp70 expression in response to adriamycin
treatment11.  In this regard, mice deficient in alpha-B-crystal-
lin and HspB2 (two small Hsps related to Hsp25) show
decreased total glutathione levels in the heart and increased
susceptibility to ischemia-reperfusion-induced damage,
whereas mice overexpressing alpha-B-crystallin show
increased resistance against ischemia-reperfusion22.
Increased expression of Hsp20 protects the heart from
ischemia-reperfusion-induced injury, leading to restoration
of cardiac function and reduced infarction23.
 Fig. 7. Cellular damage of left ventricular wall cardiac tissue.  The
Adr group showed the highest percentage of cellular damage
in contrast to the Temp-Adr samples, which had the least
cellular damage (8 and 12 weeks).  The percentage of cellular
damage was interpreted following a semi-quantitative scoring
cytogram system.  Values ranging from 0–4 were assigned to
cellular damage zones for all four groups.  The 100% level of
damage was related to the maximal theoretical value of 72.
The Control, Adr, Temp and Temp-Adr groups are indicated
by white columns, black columns, dotted columns and
slashed columns, respectively.  Values are shown as the
means ± standard errors.  ANOVA and Duncan post hoc test
showed significance differences among groups (p<0.05).
Statistically significant differences compared with the control
and Adr groups are indicated with a dagger and double-
dagger, respectively.
Fig. 8. Western blot analysis of Hsp25 and myosin accumulation.  In the Adr group, two bands were recognized by the anti-Hsp25 antibody at 0 and
8 weeks after treatment.  The Temp-Adr group had the densest band recognized by the same antibody (week 0) (A).  Consistent which the
highest accumulation of Hsp25, myosin also had its densest band in the Temp-Adr-treated group at 0 week.  This result was similar to that in
the Control group at 4 weeks and to that of the Temp group at week 0.  Myosin accumulation decreased more in both Adr-treated groups from
week 8 (B).  The Western blot analysis is shown above the densitometric analysis.  The Control, Adr, Temp and Temp-Adr groups are
indicated by white columns, black columns, dotted columns and slashed columns, respectively.  Values are shown as means ± standard error.
ANOVA and Duncan post hoc test showed significance differences among groups (p<0.05).  Statistically significant differences compared
with the Control and Adr groups are indicated with a dagger and double-dagger, respectively.Strauss, Rada, Tejero et al. 241
On the other hand, the recognition of Hsp25 in Adr
samples (0 and 8 weeks) may be associated with two differ-
ent stress-stimuli responses: the heart adriamycin toxic
injury immediately after treatment, and a reduction of left
ventricular wall thickness 8 weeks after treatment.  More-
over, the parallelism between the accumulation of Hsp25
and myosin in the Temp-Adr treated heart (0 week) suggests
temperature-associated cardioprotection.  However, the dim-
inution of myosin accumulation at week 8 could be related to
a significant reduction in the left ventricular wall thickness
and the higher percentage of subcellular damage.  This is in
contrast to the observations for the control rats, which grew
normally and showed continuous accumulation of myosin
throughout the experiment. 
The development of heat stress response has been
extensively studied in order to characterize the different
steps of this form of preconditioning.  It appears that chemi-
cal signal indications (such as nitric oxide and reactive oxy-
gen species, ROS) released by sublethal hyperthermic stress
trigger a complex cascade of signalling events that include
activation of protein kinase C (PKC) and mitogen-activated
protein kinases (MAPK) and culminate in increased synthe-
sis of inducible nitric oxide synthase, cyclooxygenase-2,
antioxidant enzymes and protective proteins, such as heat
stress proteins24.  Hyperthermia protects cells from adriamy-
cin-induced death through induction and phosphorylation of
small Hsps and its antiapoptotic and actin-remodeling
activities25.  The small Hsps, including human Hsp27 and the
mouse homolog Hsp25, have been shown to protect different
types of cells against oxidative stress.  Hsp25 may play an
important role in maintenance of muscle homeostasis, regu-
lation of the glutathione system and resistance to ROS in
muscle cells.  Moreover, Hsp25 overexpression above a cer-
tain threshold aids significant improvement of cardiac mor-
phology and histological appearance, as demonstrated by
decreased fibrosis and calcification and preservation of tis-
sue integrity26. 
However, the issue of whether Hsps or antioxidant
enzymes are the primary end-effector of this cardioprotec-
tion continues to be a matter of debate8.  There is increasing
evidence that alpha-Hsps are concerned with functions other
than chaperoning.  Several studies demonstrate an interac-
tion between alpha-Hsps and nucleic acids.  It is known that
an overexpression of Hsp27 in cells can promote the acceler-
ated recovery of heat shock-produced intranuclear protein
aggregates27.  An involvement of Hsp25 granules in binding
and targeting denatured substrates for accelerated degrada-
tion has also been shown.  Data revealing that the Hsp25-
luciferase granules are stained positively with antibodies to
components of the proteasome are supportive of such an
idea28.  Correlation between the total cellular level of Hsp25
phosphorylation and the formation of nuclear granules has
been shown.  Dephosphorylated alpha-Hsps seem to be very
versatile protective agents, that play a dual role in protein
and membrane protection and might also be involved in the
preservation of nucleic acid29.  On the other hand, although
Hsp25 expression levels are quite high in mature tissue, the
developmental regulation of expression appears to be of sig-
nificant importance; therefore, developmentally associated
changes cannot be completely discriminated30. 
Adriamycin affects the expression and content of myo-
cardial structural and regulatory proteins, including that of
alpha-myosin heavy chain, ventricular myosin light chain-2
isoform, brain natriuretic peptide and in particular, myosin
light chain kinase (MLCK), which may disturb the control of
coronary vessels31,32.  In support of these results, in adriamy-
cin-treated rats previously protected with L-carnitine, which
promotes Hsp70 and Hsp253,33 we observed remarkable rec-
ognition with anti-myosin light chain kinase (unpublished
results).  Moreover, the most common abnormality in
patients treated with adriamycin was the increased
afterload34 exclusively attributable to reduced left ventricu-
lar wall thickness.  In this regard, acute pressure overload
alters cardiac gene expression by mechanisms that selec-
tively regulate the translational activity of specific mRNAs.
Expression of many genes is also dependent on how effi-
ciently each mRNA is translated35. 
The direct effect of chronic adriamycin treatment on the
level of the contractile machinery provides an additional
mechanism through which anthracyclines exert their debili-
tating cardiotoxic effects36.  The decreased contractility of
individual myocytes may relate to their low myosin content
and could contribute to the reduced cardiac output produced
by adriamycin treatment37.  The demonstration that cardiac
sarcomeric myosin organization is more noticeably per-
turbed than myosin IIB or f-actin organization raises the
Fig. 9. Cartesian representation of the Principal Components
Analysis.  Mortality and cell damage were directly
correlated, while Hsp25, left ventricular wall thickness and
myosin autovectors pointed in the opposite direction.
Mortality and cell damage were antipodal variables for
myosin.  Each symbol is associated with a number
(representing time in weeks) and a letter (symbolizing the
groups).  The Control, Adr, Temp and Temp-Adr groups are
indicated by filled triangles, filled squares, filled circles and
filled diamonds, respectively.  The arrowed lines correspond
to autovectors; each autovector matches with a variable
(mortality, body weight, left ventricular wall thickness, cell
damage, myosin and Hsp25 accumulation).242 Hyperthermic Protection in Adriamycin Cardiomyopathy
intriguing possibility that cardiac sarcomeric myosin may be
a specific target that contributes to the unique sensitivity of
cardiac tissue to the toxic effects of adriamycin38.  Both
myosin and Hsp25 genes are developmentally regulated.
This regulation has been reported for the genes encoding the
MLC genes, MLCIA and MLCIV.  In addition, the two
MHC proteins, called MHCα and MHCbeta, are develop-
mentally and hormonally regulated as well as in response to
cardiac hypertrophy due to hemodynamic overload39.
In this work, as a contribution to understanding the bio-
logical role of Hsp25 induced by thermal stress and its rela-
tionship with myosin accumulation, the biologically
connected events herein discussed were mathematically inte-
grated by the biometrical and multivariate approaches.  Even
though the possible protection provided by the hyperthermic
strategy was not evident in the univariate analysis of each
variable, the PCA model proved the positive correlation
between Hsp25 accumulation, the thickness of the left ven-
tricular wall and myosin accumulation.  In addition, mortal-
ity and cell damage were found to be inversely correlated
with the accumulation of myosin.  Despite the PCA model
robustness, a few inconsistencies became evident, since the
natural process compared with the mathematical reduction
includes many more unknown variables.  However, the PCA
model represents a powerful technique in the approach to
research of biological systems.  Based on the induction of
Hsp25 and the myosin accumulation, which may enhance
the cell-protecting mechanism, hyperthermia needs further
investigation as a possible cardioprotective strategy.
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